Erratum: Aripiprazole in Children and Adolescents with Conduct Disorder: A Single-Center, Open-Label Study (Pharmacopsychiatry (2012) 45 (13-19) DOI: 10.1055/s-0031-1286348);Aripiprazole in children and adolescents with conduct disorder: A single-center, open-label study

Pharmacopsychiatry

Volumn 45, Issue 1, 2012, Pages 13-19

  Ercan, E S ^a   Uysal, T ^a   Ercan, E ^b   Ardc, U A ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b EGE UNIVERSITY   (Turkey)

Author keywords

aripiprazole; attention deficit hyperactivity disorder; conduct disorder

Indexed keywords

ARIPIPRAZOLE;

ADOLESCENT; ADULT DISEASE; ALKALINE PHOSPHATASE BLOOD LEVEL; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD CELL COUNT; CHILD; CHILD BEHAVIOR CHECKLIST; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONDUCT DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; FREE LIOTHYRONINE INDEX; GLUCOSE BLOOD LEVEL; HUMAN; IRRITABILITY; LIPID BLOOD LEVEL; LIVER FUNCTION; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHOOL CHILD; SEDATION; SIDE EFFECT; TEACHER; THYROID FUNCTION; UREA BLOOD LEVEL; URINALYSIS;

EID: 84855347523     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0035-1555802     Document Type: Erratum

References (36)

1. th ed. Washington DC American Psychiatric Association: 1994
2. Biederman J, Faraone S, Milberger S et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry: 1996; 53 437 446 (Pubitemid 26149233)
3. Loeber R, Green S M, Keenan K et al. Which boys will fare worse? Early predictors of the onset of conduct disorder in a six-year longitudinal study. J Am Acad Child Adolesc Psychiatry: 1995; 34 499 509
4. Biederman J, Petty C R, Evans M et al. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res: 2010; 177 299 304
5. Pliszka S R, Crismon M L, Hughes C W et al. Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder. The Texas Childrens Medication Algorithm Project: Revision of the Algorithm for Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry: 2006; 45 642 657
6. Pliszka S. American Academy of Child and Adolescent Psychiatry Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry: 2007; 46 894 921
7. Burris K D, Molski T F, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther: 2002; 302 381 389 (Pubitemid 34680462)
8. Jordan S, Koprivica V, Chen R et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol: 2002; 26; 441 137 140 (Pubitemid 34626163)
9. Davies M A, Sheffler D J, Roth B L. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev: 2004; 10 317 336 (Pubitemid 40128915)
10. Tamminga C A. Partial dopamine agonists in the treatment of psychosis. J Neural Transm: 2002; 109 411 420 (Pubitemid 34251643)
11. Findling R L, Robb A, Nyilas M et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry: 2008; 165 1432 1441
12. Murphy T K, Mutch P J, Reid J M et al. Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol: 2009; 19 441 447
13. Findling R L, Nyilas M, Forbes R A et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry: 2009; 70 1441 1451
14. Findling R L, Short E J, Leskovec T et al. Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol: 2008; 18 347 354
15. Marcus R N, Owen R, Kamen L et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry: 2009; 48 1110 1119
16. Tramontina S, Zeni C P, Pheula G F et al. Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/hyperactivity disorder: an open clinical trial. CNS Spectr: 2007; 12 758 762 (Pubitemid 350072173)
17. Findling R L, Kauffman R, Sallee F R et al. An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychopharmacol: 2009; 19 431 439
18. Kaufman J, Birmaher B, Brent D et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry: 1997; 36 980 988 (Pubitemid 27272932)
19. Gokler B, Unal F, Pehlivanturk B et al. Reliability and valdty of schedule for affective disorders and schizophrenia for school-age children-present and lifetime version Turkish version (K-SADS-PL-T) [in Turkish]. Cocuk ve Genclik Ruh Sagl Dergisi (Journal of Child and Adolescent Mental Health): 2004; 11 3
20. National Institute of Mental Health CGI (Clinic Global Impression) Scale. Psychopharmacology Bull: 1985; 21 839 843
21. Turgay A. Disruptive behavior disorders: child and adolescent screening and rating scales for children, adolescents, parents and teachers.West Bloomfield (Michigan). Integrative Therapy Institute Publication: 1994
22. Ercan E S, Amado S, Somer O et al. Development of a test battery for the assessment of attention deficit hyperactivity disorder [in Turkish]. Cocuk ve Genclik Ruh Sagl Dergisi (Journal of Child and Adolescent Mental Health): 2001; 8 132 144
23. Achenbach T M, Edelbrock C. Manual for the Child Behavior Checklist/418 and revised child behavior profile. Burlington, Vt University of Vermont, Department of Psychiatry: 1983
24. Erol N, Kiliç N, Ulusoy M. Mental health profile of Turkey [in Turkish], TC Saǧlik Bakanliǧi Temel Saǧlik Hizmetleri Genel Müdürlüǧü, Ankara. Turkey. 1998
25. Wechsler D. Wechsler Preschool and Primary Scale of Intelligence (Revised edition). Harcourt Brace New York: 1983
26. Burke D, Loeber R, Birmaher B. Oppositional defiant disorder and conduct disorder: A review of the past 10 years, Part II. J Am Acad Child Adolesc Psychiatry: 2002; 41 1275 1293 (Pubitemid 38338019)
27. Olfson M, Blanco C, Liu L et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry: 2006; 63 679 685 (Pubitemid 43848299)
28. Snyder R, Turgay A, Aman M. et al., Risperidone Conduct Study Group Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry: 2002; 41 1026 1036 (Pubitemid 38338050)
29. Aman M G, De Smedt G, Derivan A. et al., Risperidone Disruptive Behavior Study Group Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry: 2002; 159 1337 1346 (Pubitemid 34832715)
30. Findling R L, McNamara N K, Branicky L A et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry: 2000; 39 509 516 (Pubitemid 30185547)
31. Turgay A, Binder C, Snyder R et al. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics: 2002; 110 e34
32. Findling R L, Aman M G, Eerdekens M et al. Risperidone Disruptive Behavior Study Group Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry: 2004; 161 677 684 (Pubitemid 38445512)
33. Croonenberghs J, Fegert J M, Findling R L. et al., Risperidone Disruptive Behavior Study Group Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry: 2005; 44 64 72 (Pubitemid 40019201)
34. Reyes M, Buitelaar J, Toren P et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry: 2006; 163 402 410 (Pubitemid 44469381)
35. Lyon G J, Samar S, Jummani R et al. Aripiprazole in children and adolescents with Tourettes disorder: an open-label safety and tolerability study. J Child Adolesc Psychopharmacol: 2009; 19 623 633
36. De Hert M, Dobbelaere M, Sheridan E M et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry: 2011; 26 144 158